Sanofi SA SNYNF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNYNF is a good fit for your portfolio.
News
-
Sanofi on Pace for Largest Percent Decrease Since October 2023 — Data Talk
-
Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis
-
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
-
France's Sanofi Partners With OpenAI to Accelerate Drug Development
-
Novavax Shares Pop Another 50% Following Sanofi Deal
-
Trending: Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal
-
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit — Update
-
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal
Trading Information
- Previous Close Price
- $93.04
- Day Range
- $94.11–94.11
- 52-Week Range
- $86.12–110.16
- Bid/Ask
- $90.07 / $96.88
- Market Cap
- $117.73 Bil
- Volume/Avg
- 710 / 31,188
Key Statistics
- Price/Earnings (Normalized)
- 10.33
- Price/Sales
- 2.33
- Dividend Yield (Trailing)
- 4.32%
- Dividend Yield (Forward)
- 4.32%
- Total Yield
- 4.69%
Company Profile
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 87,994
- Website
- https://www.sanofi.com
Competitors
Valuation
Metric
|
SNYNF
|
MRK
|
NVS
|
---|---|---|---|
Price/Earnings (Normalized) | 10.33 | 58.75 | 15.21 |
Price/Book Value | 1.54 | 8.00 | 5.40 |
Price/Sales | 2.33 | 5.29 | 4.36 |
Price/Cash Flow | 11.51 | 18.59 | 14.48 |
Price/Earnings
SNYNF
MRK
NVS
Financial Strength
Metric
|
SNYNF
|
MRK
|
NVS
|
---|---|---|---|
Quick Ratio | 0.83 | 0.68 | 0.61 |
Current Ratio | 1.27 | 1.25 | 0.90 |
Interest Coverage | 8.40 | 3.97 | 11.32 |
Quick Ratio
SNYNF
MRK
NVS
Profitability
Metric
|
SNYNF
|
MRK
|
NVS
|
---|---|---|---|
Return on Assets (Normalized) | — | 5.22% | 13.39% |
Return on Equity (Normalized) | — | 13.56% | 31.09% |
Return on Invested Capital (Normalized) | — | 8.29% | 19.67% |
Return on Assets
SNYNF
MRK
NVS
Drug Manufacturers - General Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Eli Lilly and Co
LLY
| Znssydzy | Rzf | $841.1 Bil | |||
Johnson & Johnson
JNJ
| Chjwcdtj | Wwwy | $351.3 Bil | |||
Merck & Co Inc
MRK
| Mrtccvf | Qxjn | $322.9 Bil | |||
AbbVie Inc
ABBV
| Mnwnnntn | Qpsk | $299.6 Bil | |||
AstraZeneca PLC ADR
AZN
| Pqdbcgzf | Qytmx | $244.3 Bil | |||
Roche Holding AG ADR
RHHBY
| Lvjsltqkb | Qjhz | $222.8 Bil | |||
Novartis AG ADR
NVS
| Ffcxbms | Mqcp | $214.2 Bil | |||
Amgen Inc
AMGN
| Skhngcwnfz | Xvj | $162.7 Bil | |||
Pfizer Inc
PFE
| Shpwwkvjk | Rlqq | $152.9 Bil | |||
Sanofi SA ADR
SNY
| Qfhzqxg | Fzsvd | $117.4 Bil |